Re-examining the factor structure of the Insomnia Severity Index (ISI) and defining the meaningful within-individual change (MWIC) for subjects with insomnia disorder in two phase III clinical trials of the efficacy of lemborexant
Abstract Background The Insomnia Severity Index (ISI) is a widely used measure of insomnia severity. Various ISI research findings suggest different factor solutions and meaningful within-individual change (MWIC) to detect treatment response in patients with insomnia. This study examined an ISI fact...
Saved in:
Main Authors: | William R. Lenderking (Author), Yulia Savva (Author), Mark J. Atkinson (Author), Renee Campbell (Author), Isabelle Chabot (Author), Margaret Moline (Author), Genevieve Meier (Author), Charles M. Morin (Author) |
---|---|
Format: | Book |
Published: |
SpringerOpen,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
by: Yoshikazu Takaesu, et al.
Published: (2023) -
Safety and Efficacy of Lemborexant in Insomnia Patients: Results of a Postmarketing Observational Study of Dayvigo® Tablets
by: Kazuo Mishima, et al.
Published: (2024) -
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Satish Dayal, et al.
Published: (2021) -
Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
by: Ishani Landry, et al.
Published: (2020) -
Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Ishani Landry, et al.
Published: (2021)